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Introduction {#sec1}
============

During the iterative process of differentiation, intrinsic and extrinsic cues establish heterogeneity at the cell, organ, and system level. A striking paradigm for this diversification can be observed in the endothelium, which differentiates from mesoderm to form arterial, venous, lymphatic, and organ-specific vessel networks ([@bib12]). Although multiple cellular origins for endothelial cells (ECs) have been described ([@bib33], [@bib35], [@bib19], [@bib40], [@bib29], [@bib47]), the impact of cell lineage on EC diversification is poorly understood. The prevailing view is that tissue-derived signals, coupled to vessel subtype-specific transcriptional networks, establish molecular and functional heterogeneity as ECs invade different organs and tissues ([@bib34]).

The initial steps of vascular development take place during gastrulation as mesodermal progenitors commit to an endothelial fate. In zebrafish ([@bib35], [@bib27], [@bib29]), chick ([@bib48], [@bib31], [@bib5], [@bib47]), and mouse ([@bib23], [@bib15], [@bib44]), ECs have been shown to derive from both lateral plate mesoderm (LPM) and paraxial mesoderm (PXM, also known as presomitic mesoderm) ([Figure 1](#fig1){ref-type="fig"}A). Additionally, erythro-myeloid progenitor cells have been reported as a source of both yolk sac and intraembryonic ECs in mouse ([@bib33]). Whether ECs derived from these various lineages are functionally distinct, or preferentially contribute to different vascular beds is poorly understood. Intriguingly, transplantation experiments in avian embryos showed that while PXM-derived ECs contribute to the cardinal vein, wing bud, and perineural vascular plexus, they are unable to invade the visceral organs and are excluded from the ventral wall of the dorsal aorta ([@bib31]), suggesting that ECs from divergent sources may possess unique functional and molecular properties.Figure 1Paraxial Mesodermal Cells Contribute to the Cardinal Vein and Developing Lymphatics(A) Schematic representation of the contribution of lateral plate and paraxial mesoderm-derived cells to the developing endothelium.(B--B″) Immunofluorescence for PAX3 and VEGFR2 on transverse cryosections.(C--C″) Immunofluorescence for tdTomato and VEGFR2 on transverse cryosections from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(D--D″) Immunofluorescence for tdTomato, PECAM, and PROX1 on transverse vibratome sections from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(E--E″) Immunofluorescence for tdTomato, EMCN, and LYVE1 on transverse cryosections from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(F) Immunofluorescence for tdTomato, EMCN, and LYVE1 on transverse cryosections from a *Myf5*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(CV, cardinal vein; Ao, aorta; DM, dermomyotome; NT, neural tube; JLS, jugular lymph sac; JV, jugular vein.)Scale bars: 50 μm (B, C, E′, and E″); 20 μm (C′ and C″); 100 μm (D, E, and F).

The cellular origin of lymphatic vessels has been the subject of debate for over a century ([@bib42], [@bib39], [@bib14], [@bib36]). Live imaging in zebrafish showed that lymphatic ECs (LECs) arise from venous endothelium ([@bib50]), and lineage tracing analyses in mouse have shown that the majority of LECs are derived from transdifferentiation of venous ([@bib39]), intersegmental ([@bib49]), and capillary ([@bib32]) blood ECs. Additionally, contribution of hemogenic endothelium-derived cells to lymphatics in the mesentery ([@bib40]) and heart ([@bib19]) has been reported in mouse. Furthermore, studies in *Xenopus* ([@bib30]) and avian models ([@bib46], [@bib38]) have suggested alternative nonendothelial sources of LECs, including the PXM.

Following specification from the anterior primitive streak, the PXM extends bilaterally along the anterior-posterior axis adjacent to the neural tube ([@bib13]). Segmentation of the PXM creates the somites, transient structures that contain progenitors for a number of tissues including bone, dorsal dermis, skeletal muscle, and the endothelium of the limb ([@bib4]). In chick, clonal analyses of individual somitic cells identified bipotent precursors for the skeletal muscle and endothelium of the limb ([@bib16]), while cells coexpressing PAX3 (a marker of myogenic precursors) and VEGFR2 (vascular endothelial growth factor receptor 2) have been observed in the somite of the mouse ([@bib23], [@bib16]). Genetic lineage tracing using Cre recombinase alleles driven from the endogenous transcription start site of the *Pax3* and *Myf5* (myogenic factor 5) genes demonstrated a common origin for skeletal muscle and a subset of the endothelium in the mouse limb ([@bib15]). Furthermore, the descendants of VEGFR2-expressing cells contribute to both endothelium and skeletal muscle in mouse ([@bib28]). Collectively, these data reveal the existence of a common bipotent progenitor for skeletal muscle and endothelium.

Here, we systematically analyzed the contribution of PXM-derived cells (PXMDCs) to the endothelium of different vascular networks to determine the impact of lineage history on the terminal fate of ECs. Using Cre-loxP-based lineage tracing and high-resolution imaging, these analyses have revealed that PXMDCs are preferentially localized to the dorsal aspect of the cardinal vein before the expression of the earliest known markers of lymphatic differentiation. PXM-derived ECs selectively transdifferentiate from the cardinal vein to form LEC progenitors and subsequently give rise to the lymphatic endothelium of multiple organs and tissues, including the cardiopulmonary system, skin and liver, as well as capillary-derived LEC clusters in the embryonic skin. In addition to *Pax3*-lineage somitic muscle progenitors, we also identified a contribution of *Myf5*-lineage cells to lymphatics in the meninges and postnatal skin of the ear, and revealed the anterior second heart field (the cellular origin of a subset of head and neck muscles) as the source of a limited number of anterior jugular lymph sac, cardiac, and dermal LECs. Furthermore, by deleting *Prox1* specifically in the PXM, we find this to be the only lineage competent for LEC differentiation. Collectively, our analyses identify the earliest step in the formation of the lymphatic vasculature and reveal a common progenitor for skeletal muscle and lymphatic endothelium.

Results {#sec2}
=======

Paraxial Mesodermal Cells Contribute to the Cardinal Vein and Developing Lymphatics {#sec2.1}
-----------------------------------------------------------------------------------

Genetic lineage tracing has demonstrated the presence of a multipotent progenitor population in the mouse dermomyotome (a subset of the somitic PXM) that is marked by the expression of PAX3 and MYF5 ([Figure S1](#mmc1){ref-type="supplementary-material"}A), and gives rise to skeletal muscle and endothelium ([@bib4]). To examine their contribution to different vascular beds, we lineage traced PXMDCs using established Cre driver lines (*Pax3*^*Cre*^ \[[@bib7]\], *Pax7*^*Cre*^ \[[@bib17]\], *Myf5*^*Cre*^ \[[@bib41]\]) and a ubiquitously expressed lineage reporter (*Rosa26*^*tdTomato*^ \[[@bib21]\]) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). We found that PXMDCs contribute to the endothelium of the embryonic forelimb ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1D′) and gastrocnemius muscle of the adult hindlimb ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1E′) confirming previous observations ([@bib23], [@bib15]). Analysis of transverse sections from *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ embryos at E9 revealed contribution of PXMDCs to the endothelium of the perineural vascular plexus, intersegmental vessels, and the dorsolateral wall of the developing cardinal vein ([Figures 1](#fig1){ref-type="fig"}C--1C″, [S1](#mmc1){ref-type="supplementary-material"}F, and S1F′). LEC progenitors are known to differentiate from the dorsolateral wall of the cardinal vein under the transcriptional control of SOX18, COUPTFII, and PROX1 ([@bib8], [@bib39], [@bib51], [@bib45]), and previous studies have reported a contribution of somitic cells to the lymphatic endothelium in avian embryos ([@bib46], [@bib11], [@bib38]). Therefore, we investigated whether PXMDCs contribute to the lymphatic endothelium using immunofluorescence for established LEC markers. Analysis of transverse sections from *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ embryos at E10.5 demonstrated that PROX1-positive LEC progenitors located within and migrating from the cardinal vein were derived from the PXM ([Figures 1](#fig1){ref-type="fig"}D--1D″). Subsequently, we found these cells migrating from the cardinal vein to form the jugular lymph sacs (JLS) ([Figures 1](#fig1){ref-type="fig"}E--1E″). To determine the spatiotemporal pattern of differentiation from the dermomyotome, we lineage traced PXMDCs using *Pax7*^*Cre*^ (restricted to the central dermomyotome; [Figure S1](#mmc1){ref-type="supplementary-material"}A) and *Myf5*^*Cre*^ (later onset of expression during myogenic lineage commitment; [Figure S1](#mmc1){ref-type="supplementary-material"}B) lines. Consistent with a previous report ([@bib15]), we observed contribution of the *Myf5* ([Figure 1](#fig1){ref-type="fig"}F), but not the *Pax7* lineage ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H), to the endothelium. *Myf5* lineage cells also contributed to the embryonic lymph sacs, albeit to a lesser extent than *Pax3* lineage cells ([Figure 1](#fig1){ref-type="fig"}F), indicating that commitment of PXMDC to the lymphatic endothelium is initiated before the onset of *Myf5* expression in the dermomyotome. Collectively, these data indicate that LEC fate may become hard wired as cells transition through the PXM lineage.

Cardiopulmonary, Subcutaneous, and Dermal Lymphatics Are Derived from the Paraxial Mesoderm {#sec2.2}
-------------------------------------------------------------------------------------------

To determine their contribution to the endothelium of different lymphatic beds, we lineage traced PXMDCs and analyzed whole-mount tissues and sections at various embryonic stages. Sagittal vibratome sections of E13.5 *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ embryos immunostained for PROX1 and PECAM revealed labeling of LECs migrating into the cardiopulmonary system with limited or no contribution to blood ECs (BECs) ([Figures 2](#fig2){ref-type="fig"}A--2A″). PXMDCs initially migrate onto the ventral side of the embryonic lung ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Imaging of fetal and adult hearts revealed that most cardiac LECs were labeled in *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ animals ([Figure S2](#mmc1){ref-type="supplementary-material"}B), reflecting the migration of PXMDCs from the venous endothelium, which is the source of most cardiac LECs ([@bib19]). The lymphatic vasculature of the embryonic skin has been shown to form through lymphangiogenic sprouting from the JLS in the cervicothoracic region and differentiation from the dermal capillary plexus in the lumbar dermis and the cervicothoracic midline ([@bib32]). Sagittal vibratome sections of E13.5 *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ ([Figures 2](#fig2){ref-type="fig"}B--2B″) and *Myf5*^*Cre*^*;Rosa26*^*tdTomato*^ ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2C‴) embryos immunostained for podoplanin (PDPN) and PROX1 revealed that subcutaneous LECs spanning the lateral lumbar region are PXM-derived. Analysis of E13.5 whole-mount skin immunostained for PECAM and NRP2 showed that the superficial thoracic dermal LECs ([Figures 2](#fig2){ref-type="fig"}C, 2C′, [S3](#mmc1){ref-type="supplementary-material"}D, and S3F), which migrate from the JLS, and the clustered lumbar dermal LECs ([Figures 2](#fig2){ref-type="fig"}D, 2D′, [S3](#mmc1){ref-type="supplementary-material"}E, and S3G), which arise from the dermal capillary plexus, are initially derived from the PXM. These data indicate that dermal LECs differentiate from venous and dermal capillary progenitor populations that share a common PXM origin. At later embryonic stages, PXMDCs comprise the lymphatic endothelium of the thoracic, lumbar, and sacral dermis ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3K‴). However, analysis of whole-mount skin immunostained for PECAM, NRP2, and PROX1 revealed that the lymphatic endothelium of the cervical skin is a mixture of cells from *Pax3*^*+ve*^ and *Pax3*^*-ve*^ lineages ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3B‴).Figure 2Paraxial Mesodermal Cells Give Rise to the Cardiopulmonary, Subcutaneous, and Dermal Lymphatics(A--A″) Immunofluorescence for tdTomato, PECAM, and PROX1 on a sagittal vibratome section at the level of the cardiac outflow tract from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(B--B″) Immunofluorescence for tdTomato, PECAM, and PROX1 on a sagittal vibratome section at the level of the subcutaneous lymphatic network from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryo.(C--D′) Immunofluorescence for tdTomato, NRP2, and PECAM on whole-mount skin from *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ embryos at the indicated positions and stages.(Ao, aorta; Ot, outflow tract.)Scale bars: 500 μm (A); 200 μm (B); 100 μm (A′ and A″); 50 μm (C); 20 μm (C′--D′).

Distinct Muscle Progenitor Populations Give Rise to Lymphatics {#sec2.3}
--------------------------------------------------------------

PAX3 labels myogenic precursors in the somitic PXM, but independent gene regulatory networks control myogenesis in the head and neck ([@bib2]); the contribution of *Pax3* lineage cells to the lymphatic endothelium may be spatially restricted in a similar manner. While the expression of PAX3 is limited to the somitic PXM, myogenic regulatory factors such as MYF5 determine muscle fate throughout the body ([@bib2]). Analysis of the head lymphatics in E13.5 *Myf5*^*Cre*^*;Rosa26*^*tdTomato*^ embryos revealed a contribution of *Myf5* lineage cells to the lymphatic endothelium of the lower jaw ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3C‴), a population of LECs that is not labeled in *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ embryos. To understand whether other populations of muscle progenitors may also serve as LEC progenitors, we next analyzed the *Mef2c-AHF*^*Cre*^ line, which labels derivatives of the anterior second heart field ([@bib43]). A subset of the head and neck muscles have been shown to derive from multipotent progenitor cells that also give rise to second heart field-derived regions of the heart ([@bib6]). These muscles are labeled in *Mef2c-AHF*^*Cre*^, but not in *Pax3*^*Cre*^ mice ([@bib20]). Sagittal vibratome sections of E13.5 *Mef2c-AHF*^*Cre*^*;Rosa26*^*tdTomato*^ embryos stained for PROX1 and PDPN revealed labeling of a small number of LECs in the anterior JLS ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3D′). Furthermore, imaging of embryonic hearts immunostained for CDH5 and PROX1 showed that a minor proportion of ventral cardiac LECs are also labeled in *Mef2c-AHF*^*Cre*^*;Rosa26*^*tdTomato*^ animals ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3E′). Moreover, analysis of whole-mount skin revealed a contribution of the *Mef2c-AHF* lineage to the cervicothoracic dermal capillary plexus ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3F′) and lymphatic endothelium ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3G′). Collectively, these data indicate that LECs may arise from multiple anatomically distinct muscle progenitor populations.

Paraxial Mesoderm-Derived Cells Form Organ-Specific Lymphatic Networks {#sec2.4}
----------------------------------------------------------------------

To determine their contribution to the postnatal and adult lymphatic endothelium, we lineage traced PXMDCs and analyzed whole-mount tissues and sections. Imaging of adult hearts from *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ animals revealed labeling of a network of vessels at the surface of the heart ([Figure 3](#fig3){ref-type="fig"}A). Immunostaining for LYVE1 and PDPN showed that most of cardiac LECs are PXM-derived ([Figure 3](#fig3){ref-type="fig"}A′) with no contribution of PXMDCs to the coronary endothelium. Immunostaining of lung sections from *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ animals showed that PXMDCs give rise to lymphatic vessels that sit proximal to the airways and major vessels ([Figures 3](#fig3){ref-type="fig"}B--3B″), with limited contribution to blood vessel endothelium, while analysis of liver tissue from *Pax3*^*Cre*^*;Rosa26*^*tdTomato*^ animals showed that LECs in this tissue are PXM-derived ([Figures 3](#fig3){ref-type="fig"}C--3C″), and also revealed a contribution of PXMDCs to the hepatic blood vessel endothelium ([Figure S3](#mmc1){ref-type="supplementary-material"}H). In contrast to all other visceral organs examined, we did not observe a contribution of PXMDCs to the mesenteric or intestinal lymphatics ([Figures S3](#mmc1){ref-type="supplementary-material"}I and S3I′). Immunostaining of whole-mount meninges ([Figures 3](#fig3){ref-type="fig"}D--3D″) and ear skin ([Figures S3](#mmc1){ref-type="supplementary-material"}J--S3K′) revealed that the LECs in these lymphatic beds are derived from a *Myf5*^*+ve*^ muscle progenitor population with no contribution from the *Pax3* lineage.Figure 3Paraxial Mesoderm-Derived LECs Form the Lymphatic Vasculature of Postnatal and Adult Tissues(A) Representative whole-mount stereoscopic imaging of the adult heart from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ animal.(A′) Whole-mount immunofluorescence for tdTomato, LYVE1, and PDPN on the adult ventricle from a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ animal.(B--B″) Immunofluorescence for tdTomato, PECAM, and PDPN on cryosectioned lung tissue from a postnatal day 21 *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ mouse.(C--C″) Immunofluorescence for tdTomato, LYVE1, and VEGFR2 on cryosectioned liver tissue from the caudal lobe of a *Pax3*^*Cre/+*^*;Rosa26*^*tdtomato*^ animal.(D--D″) Whole-mount immunofluorescence for tdTomato, LYVE1, and PDPN on the adult meninges from a *Myf5*^*Cre/+*^*;Rosa26*^*tdtomato*^ animal.Scale bars: 100 μm (A′ and B--B″); 250 μm (C--C″); 50 μm (D--D″).

Transition through the Paraxial Mesodermal Lineage Is Essential for Lymphatic Endothelial Differentiation {#sec2.5}
---------------------------------------------------------------------------------------------------------

To determine the requirement for PXMDCs during the formation of the lymphatic vasculature (i.e., do cells derived from other mesodermal subtypes have the capacity to differentiate into LECs when this process is impaired in PXMDCs), we conditionally deleted the master regulator of LEC fate *Prox1* ([@bib45]) in the PXM lineage. For these analyses, we crossed a conditional *Prox1*^*fl*^ allele ([@bib22]) with *Pax3*^*Cre*^ and examined lymphatic development. Gross morphological assessment revealed that homozygous loss of *Prox1* in the PXM lineage leads to subdermal edema and blood-filled lymphatic vessels in the cervical and thoracic skin at E15.5 ([Figures 4](#fig4){ref-type="fig"}A and 4B). Detailed morphological analyses of sagittal vibratome sections immunostained for PDPN, PECAM, and PROX1 showed a lack of subcutaneous LECs in the lateral lumbar region of *Pax3*^*Cre*^*;Prox1*^*fl/fl*^ embryos at E13.5 ([Figures 4](#fig4){ref-type="fig"}C--4D′). Furthermore, analysis of whole-mount skin immunostained for PECAM and NRP2 revealed a complete lack of lumbar dermal lymphatics at E15.5 ([Figures 4](#fig4){ref-type="fig"}E--4F′). Conditional knock out of *Prox1* in the *Tie-2* lineage was previously shown to result in incomplete recombination and the presence of a dysmorphic cardiac lymphatic network ([@bib19]). Analysis of sagittal vibratome sections at the level of the cardiac outflow tract showed the presence of PXM-derived LECs that expressed low levels of PROX1 in the anterior region of the lung in *Pax3*^*Cre*^*;Prox1*^*fl/fl*^*;Rosa26*^*tdTomato*^ embryos at E13.5 ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4B′). Furthermore, analysis of whole-mount skin revealed the presence of PROX1-expressing LECs in the thoracic and cervical dermis in *Pax3*^*Cre*^*;Prox1*^*fl/fl*^*;Rosa26*^*tdTomato*^ embryos at E15.5 ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4H′), indicating that recombination of the *Prox1*^*fl*^ allele is incomplete in certain lymphatic beds. Collectively, these data show an absence of LEC differentiation where complete recombination of *Prox1* is achieved in the PXM lineage, indicating that the PXM may be the only mesodermal subtype competent for LEC differentiation.Figure 4Transition through the Paraxial Mesodermal Lineage Is Essential for LEC DifferentiationWhole-mount brightfield images of *Prox1*^*fl/fl*^ (A) and *Pax3*^*Cre/+*^*;Prox1*^*fl/fl*^ embryos (B) at E15.5. Immunofluorescence for PDPN, PECAM, and PROX1 on sagittal vibratome sections at the level of the subcutaneous lymphatic network from *Prox1*^*fl/fl*^ (C) and *Pax3*^*Cre/+*^*;Prox1*^*fl/fl*^ embryos (D) at E13.5. Immunofluorescence for PECAM and NRP2 on whole-mount lumbar skin from *Prox1*^*fl/fl*^ (E and E′) and *Pax3*^*Cre/+*^*;Prox1*^*fl/fl*^ embryos (F and F′) at E15.5.Scale bars: 100 μm (C--D′); 200 μm (E--F′).

Discussion {#sec3}
==========

Our study shows that contrary to current dogma, terminal EC fate is imprinted during mesodermal differentiation and before initiation of the established endothelial genetic program. Akin to the contribution of the first and second heart fields to distinct regions of the heart ([@bib18]), and the allocation of preconfigured cells to anterior versus posterior fates in the nervous system ([@bib25]), this work reveals that ECs can be functionally subdivided based on their embryonic origin. In avian embryos, LECs have been shown to derive from both the LPM and PXM ([@bib46], [@bib48]). While accurate lineage tracing of the cranial PXM is currently not possible because of the lack of a distinct morphological and molecular boundary with the cranial LPM ([@bib37]), lineage tracing with *Myf5*^*Cre*^ indicates that distinct muscle progenitor populations give rise to LECs in the head. Furthermore, lineage tracing with *Mef2c-AHF*^*Cre*^ identified the second heart field as an additional local progenitor source for LECs in the neck and heart. Collectively, our data indicate that multiple classically defined muscle progenitor populations serve as the cellular source of LECs in distinct anatomical locations.

Our analyses show that LECs in the mouse cardiopulmonary, liver, meningeal, subcutaneous, and dermal lymphatic vessels derive from the PXM lineage, which also makes a more limited and tissue-restricted contribution to the blood vasculature; for example, PXM-derived blood ECs were rarely observed in the heart or lung, but fairly frequently in the liver. A recent study in mouse reported that yolk sac and embryonic erythro-myeloid progenitors are the cellular source of up to 60% of liver ECs ([@bib33]); however, whether erythro-myeloid progenitor-derived ECs are functionally distinct from neighboring ECs was not established. Intriguingly, in an aortic endothelial injury model, a subpopulation of highly proliferative ECs was shown to drive regeneration of the endothelial layer ([@bib24]), highlighting the functional heterogeneity of neighboring ECs within individual vessels. Future studies comparing PXM-derived ECs with neighboring ECs may reveal important aspects of endothelial heterogeneity that may impact the physiological response of entire vessel networks.

Lymphatic diseases represent a significant healthcare burden with estimates of up to 300 million individuals suffering from primary or secondary lymphedema worldwide ([@bib1]). Recent genome-wide analyses have uncovered novel molecular players in the development of primary lymphedema; however, the genetic basis of more than 75% of all cases is currently unknown ([@bib3]). Furthermore, current therapies for secondary lymphedema are palliative ([@bib10]). Our findings identify the earliest step in LEC differentiation, which precedes induction of LEC fate by the well-described SOX18-COUPTFII-PROX1 axis ([@bib9]). It is thus likely that investigation of the molecular cues that drive specification of LECs from the PXM will help the discovery of novel causative mutations in primary lymphatic disease in humans. Furthermore, future efforts to define the signals that drive PXM to LEC differentiation *in vivo* may provide a framework to differentiate progenitor cells into LECs, which could be used to treat secondary lymphedema. Notably, as the roles of lymphatics in cancer, cardiovascular disease, immunity, and infection are being described in increasing depth ([@bib26]), our findings may also have broad implications for human pathophysiology.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti-VEGFR2BD PharmingenCat\# 550549; RRID:[AB_2132506](nif-antibody:AB_2132506){#intref0010}Mouse anti-PAX3R&D SystemsCat\# MAB2457; RRID:[AB_2159398](nif-antibody:AB_2159398){#intref0015}Rat anti-CD31 (PECAM)BD PharmingenCat\# 553370;\
RRID:[AB_394816](nif-antibody:AB_394816){#intref0020}Rabbit anti-PROX1Reliatech GmbHCat\# 102-PA32AGRabbit anti-PROX1ProteintechCat\# 11067--2-AP; RRID:[AB_2268804](nif-antibody:AB_2268804){#intref0025}Rat anti-EMCNSanta Cruz BiotechnologyCat\# SC-65495; RRID:[AB_2100037](nif-antibody:AB_2100037){#intref0030}Rat anti-LYVE1Reliatech GmbHCat\# 103-PA50,Hamster anti-PDPNDevelopmental Studies Hybridoma BankRRID:[AB_531893](nif-antibody:AB_531893){#intref0035}Goat anti-NRP2R&D SystemsCat\# AF567; RRID:[AB_2155253](nif-antibody:AB_2155253){#intref0040}Rabbit anti-ACTA2GeneTexCat\# GTX100034; RRID:[AB_1240408](nif-antibody:AB_1240408){#intref0045}CD144 (CDH5)BD Pharmingen,Cat\# 555289; RRID:[AB_395707](nif-antibody:AB_395707){#intref0050}Alexa Fluor® 405, Goat anti-Rabbit IgG (H+L)Thermo Fisher ScientificCat\# A-31556; RRID:[AB_221605](nif-antibody:AB_221605){#intref0055}Alexa Fluor® 488, Goat anti-Rat IgG (H+L)Thermo Fisher ScientificCat\# A-11006; RRID:[AB_2534074](nif-antibody:AB_2534074){#intref0060}Alexa Fluor® 488, Goat anti-Hamster IgG (H+L)Thermo Fisher ScientificCat\# A-21110; RRID:[AB_141509](nif-antibody:AB_141509){#intref0065}Alexa Fluor® 488, Goat anti-Mouse IgG2a IgG (H+L)Thermo Fisher ScientificCat\# A-21131; RRID:[AB_141618](nif-antibody:AB_141618){#intref0070}Alexa Fluor® 647, Goat anti-Rabbit IgG (H+L)Thermo Fisher ScientificCat\# A-21244; RRID:[AB_141663](nif-antibody:AB_141663){#intref0075}Alexa Fluor® 647, Goat anti-Rat IgG (H+L)Thermo Fisher ScientificCat\# A-21247; RRID:[AB_141778](nif-antibody:AB_141778){#intref0080}Alexa Fluor® 647, Donkey anti-Goat IgG (H+L)Thermo Fisher ScientificCat\# A-21447; RRID:[AB_141884](nif-antibody:AB_141884){#intref0085}**Chemicals, Peptides, and Recombinant Proteins**DAPISigmaCat\# D954ParaformaldehydeSigmaCat\# P6148Phosphate-buffered saline tabletSigmaCat\# P4417Triton X-100SigmaCat\# X-100Tween 20SigmaCat\# P1379Bovine Serum AlbuminSigmaCat\# A9418Normal Goat SerumThermo Fisher ScientificCat\# 16210072Vectashield®Vector LaboratoriesCat\# H-1000Tissue-Tek® O.C.T. compoundVWRCat\# 25608--930**Experimental models: Organisms/Strains***Pax3*^*tm1(cre)Joe*^[@bib7]MGI:[3804315](mgi:3804315){#intref0090}*Pax7*^*tm1(cre)Mrc*^[@bib17]MGI:[3510832](mgi:3510832){#intref0095}*Myf5*^*tm3(cre)Sor*^[@bib41]IMSR_JAX007893*Tg(Mef2c-cre)2Blk*[@bib43]MGI:[3639735](mgi:3639735){#intref0100}*Gt(ROSA)26Sor*^*tm9(CAG-tdTomato)Hze*^[@bib21]IMSR_JAX007909*Prox1*^*tm1a*^*(EUCOMM)*^*Wtsi*^[@bib22]MGI:[5617984](mgi:5617984){#intref0105}**Oligonucleotides***Pax3* FwCTGCACTCGGTGTCACG*Pax3*^*Cre*^ genotyping*Pax3* mut RevAGGCAAATTTTGGTGTACGG*Pax3* wt RevAAGCGAGCACAGTGCGGC*Pax7* wt Fw_1CTCCTCCACATTCCTTGCTC*Pax7*^*Cre*^ genotyping*Pax7* wt Fw_2CGGCCTTCTTCTAGGTTCTG*Pax7* mut Rev_1GCGGTCTGGCAGTAAAAACTATC*Pax7* mut Rev_2GTGAAACAGCATTGCTGTCACTT*Myf5* FwAACCAGAGACTCCCCAAGGT*Myf5*^*Cre*^ genotyping*Myf5* wt RevCGGCTCTTAAAGCAATGGTC*Myf5* mut RevACGAAGTTATTAGGTCCCTCGAC*Cre* FwATTGCTGTCACTTGGTCGTGGC*Mef2c-AHF*^*Cre*^ genotyping*Cre* RevGGAAAATGCTTCTGTCCGTTTGC*Mef2c-AHF*^*Cre*^ genotyping*Rosa26tdtomato* wt FwAAGGGAGCTGCAGTGGAGTA*Rosa26*^*tdTomato*^ genotyping*Rosa26tdtomato* wt RevCCGAAAATCTGTGGGAAGTC*Rosa26tdtomato* mut FwGGCATTAAAGCAGCGTATCC*Rosa26tdtomato* mut RevCTGTTCCTGTACGGCATGG*Prox1 flox* (a)TGCTGAAGATGTTGGTTGCT*Prox1*^*fl*^ genotyping*Prox1 flox* (b)GGCTTTTCTGTTGCTGAAGG*Prox1 flox* (c)CTGAACTGATGGCGAGCTCAGAC

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Didier Y.R. Stainier (<didier.stainier@mpi-bn.mpg.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Animals were maintained under standard conditions and all experiments were conducted in accordance with institutional (MPG) and national (Regierungspraesidium, Darmstadt) ethical and animal welfare guidelines. All mouse lines were used as previously described (*Pax3*^*Cre*^ ([@bib7]) (RRID:MGI:3804315), *Pax7*^*Cre*^ ([@bib17]) (RRID:MGI:3510832), *Myf5*^*Cre*^ ([@bib41]) (RRID:IMSR_JAX007893), *Mef2c-AHF*^*Cre*^ ([@bib43]) (MGI:[3639735](mgi:3639735){#intref0115}), *Rosa26*^*tdTomato*^ ([@bib21]) (RRID:IMSR_JAX007909) and *Prox1*^*fl*^ ([@bib22]) (MGI:[5617984](mgi:5617984){#intref0120})) and maintained on a C57BL/6J background. For embryonic staging, the morning of the vaginal plug was considered E0.5. For analyses at E10.5 and earlier, staging was performed by counting somite pairs, and at E12.5 and later by timing of the vaginal plug.

Method Details {#sec4.4}
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### Immunostaining and Imaging of Mouse Tissues {#sec4.4.1}

The following antibodies were used for immunofluorescence staining of cryosections, vibratome sections and whole mount tissues: VEGFR2 (1:200), PAX3 (1:100), CD31 ((PECAM) 1:100), PROX1 (1:200), PROX1 (1:100), EMCN (1:50), LYVE1 (1:250), PDPN (1:20), NRP2 (1:250), ACTA2 (1:400) and CD144 ((CDH5) 1:100). Alexa Fluor conjugated secondary antibodies (Thermo Fisher) were used at 1:300 in all cases.

For immunofluorescence staining of cryosections, samples were fixed in 4% paraformaldehyde (PFA) overnight at 4°C. Samples were washed in 1X PBS, then cryoprotected in sucrose and mounted in Optimal Cutting Temperature (OCT) compound. 8-10 μm cryosections were cut using a Leica CM1950 cryostat. Sections were blocked (1X PBS containing 0.1% Triton X-100 (PBX), 1% Bovine Serum Albumin (BSA) and 2% Normal Goat Serum (NGS)) for 1 hours at RT and then primary antibodies diluted in blocking buffer were incubated overnight. Following three 10-minute washes in PBX, secondary antibodies diluted in blocking buffer were incubated for 1 hours at RT. Slides were then washed three times (10 min) in PBX and where indicated, samples were counterstained with DAPI for visualization of cell nuclei before mounting with Vectashield^®^ Antifade Mounting Medium (CA, USA).

For immunofluorescence staining of vibratome sections, samples were fixed in 4% PFA overnight at 4°C, washed in 1X PBS and then mounted in 5% low melting temperature agarose. 150-200 μm vibratome sections were cut using a Leica VT1000S. Tissue slices were incubated in blocking buffer (1X PBS containing 0.5% Triton X-100, 0.5% Tween 20, 1% BSA and 3% NGS) for 2 hours at RT and then incubated with primary antibodies diluted in incubation buffer (1X PBS containing 0.25% Triton X-100, 0.25% Tween 20, 0.5% BSA and 1.5% NGS) overnight at 4°C. After primary antibody incubation, tissues were washed 5 times in PBX and then incubated with Alexa Fluor conjugated secondary antibodies for 3 hours at room temperature. Tissues were then washed 5 times in PBX and mounted in Vectashield^®^.

For whole mount staining of the embryonic skin, tissues were fixed in 4% PFA for 2 hours at RT, washed in 1X PBS and then incubated in blocking solution (1X PBS containing 0.3% Triton X-100 and 3% milk) for 2 hours at RT. Tissues were then incubated with primary antibodies diluted in blocking solution overnight at 4°C. After primary antibody incubation, tissues were washed 5 times in PBX and then incubated with Alexa Fluor conjugated secondary antibodies for 3 hours at room temperature. Tissues were then washed 5 times in PBX and mounted in Vectashield^®^.

For whole mount imaging of the heart and lungs, samples were fixed in 4% PFA overnight at 4°C, washed in 1X PBS and then blocked (1X PBS containing 0.1% Triton X-100 (PBX), 1% Bovine Serum Albumin (BSA) and 2% Normal Goat Serum (NGS)) for 3 hours at RT. Samples were incubated overnight at 4°C with primary antibodies diluted in incubation buffer (1X PBS containing 0.25% Triton X-100, 0.25% Tween 20, 0.5% BSA and 1.5% NGS). After primary antibody incubation, tissues were washed 5 times in PBX and then incubated with Alexa Fluor conjugated secondary antibodies overnight at 4°C. Tissues were then washed 5 times in PBX and mounted in 2% low melting temperature agarose for imaging.

For whole mount staining of the meninges, tissues were fixed while still attached to the skull cap in 4% PFA for 4 hours at 4°C. Following dissection of the dura mater/arachnoid from the skull cap, tissues were washed in 1X PBS and then incubated in blocking solution (1X PBS containing 0.1% Triton X-100 (PBX), 1% Bovine Serum Albumin (BSA) and 2% Normal Goat Serum (NGS)) for 3 hours at RT. Tissues were then incubated with primary antibodies diluted in blocking solution overnight at 4°C. After primary antibody incubation, tissues were washed 5 times in PBX and then incubated with Alexa Fluor conjugated secondary antibodies for 3 hours at room temperature. Tissues were then washed 5 times in PBX and mounted on glass slides in Vectashield^®^. Imaging of immunofluorescence stained tissues was performed using a Zeiss LSM700 upright or LSM800 inverted (RRID:[SCR_015963](rridsoftware:SCR_015963){#intref0125}) confocal microscope. Whole mount imaging of freshly dissected embryos at E16.5 and adult hearts was performed using a Nikon SMZ25 stereomicroscope.
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